SAN DIEGO, CA / ACCESSWIRE / February 6, 2019 / DtheraTM Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer, will be speaking at a NASA-sponsored workshop on cutting edge and emerging technologies for space health. The Workshop will be hosted by the Translational Research Institute for Space Health (TRISH) and will be held at MIT Media Lab in Cambridge, MA from February 6-7, 2019.
The workshop is intended to bring together ideas and evidence that are expected to make major contributions to the understandings of how the environment of a spacecraft can be enriched to maximize human health - specifically behavioral and cognitive health. Discussion will range from the human relationship with a broader ecology to the frontiers of digital interactions that can augment our spaces.
The TRISH is a cooperative agreement between NASA's Human Research Program (HRP), Baylor College of Medicine, the California Institute of Technology (CalTech), and Massachusetts Institute of Technology (MIT). The mission of the TRISH is to lead a national effort in translating cutting edge emerging terrestrial biomedical research and technology development into applied space flight human risk mitigation strategies for human exploration missions.
Mr. Keene will discuss how digital therapeutics, facial expression recognition, and cognitive-behavioral therapies can be used to support human health during long-duration exploration missions. These innovations are based on those incorporated into Dthera's development-stage digital therapeutic device, DTHR-ALZ, which has been granted Breakthrough Device designation by the FDA for the treatment of the symptoms of Alzheimer's disease.
About Dthera Sciences
Dthera Sciences (OTCQB: DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. Dthera is developing DTHR-ALZ, a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. To the company's knowledge, DTHR-ALZ is the first product to receive Breakthrough Device designation for the treatment of Alzheimer's disease, and Dthera Sciences is only the second digital therapeutic company to receive this designation. If granted approval by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease. Please see www.dthera.com for more information.
Forward Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of therapeutic products and technologies, as well as the Company's efforts to increase its customer base. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
CONTACT:
Company Contact
Geno Kostikov, Corporate Development
Dthera Sciences
[email protected]
(858) 215-5597
SOURCE: Dthera Sciences